Calciject PMD Solution for Injection
Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Summary of Product characteristics
(SPC)
12-06-2017
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
Calcium gluconate; Magnesium hypophosphite; Dextrose monohydrate; Boric acid
Available from:
Norbrook Laboratories Limited
ATC code:
QA12AA20
INN (International Name):
Calcium gluconate; Magnesium hypophosphite; Dextrose monohydrate; Boric acid
Dosage:
Not Currently Available
Pharmaceutical form:
Solution for injection
Prescription type:
LM: Licensed Merchant as defined in relevant national legislation
Therapeutic group:
Sheep
Therapeutic area:
calcium (different salts in combination)
Therapeutic indications:
Vitamins and minerals
Authorization status:
Authorised
Authorization date:
1991-10-01
Summary of Product characteristics
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Calciject PMD Solution for Injection
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
For a full list of excipients, see Section 6.1.
3 PHARMACEUTICAL FORM
Solution for injection.
A clear pale yellow sterile aqueous solution.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Sheep.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Calciject PMD is indicated in the treatment of hypocalcaemia
complicated by a deficiency of magnesium with
accompanying hypoglycaemia.
4.3 CONTRAINDICATIONS
None.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
No special warnings.
Each ml contains:
Active Substance
Calcium Gluconate
166 mg
Boric Acid
34 mg
Dextrose Monohydrate
200 mg
Magnesium Hypophosphite
50 mg
(as hexahydrate)
Excipients
Chlorocresol (as preservative)
1 mg
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_8_
_/_
_0_
_8_
_/_
_2_
_0_
_1_
_4_
_C_
_R_
_N_
_ _
_7_
_0_
_1_
_3_
_8_
_3_
_1_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
The solution should be warmed to body temperature before
administration.
Intravenous injections should be given slowly
and stopped at the first signs of adverse reaction.
Rapid intravenous injection may result in cardiac arrhythmias and, in
severely toxaemic animals, collapse and death.
As intravenous administration of this product could cause death, this
route should only be used by a veterinary surgeon.
SPECIAL
Read the complete document
